Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

M28 Capital Management LP​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

M28 Capital Management LP​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
M

M28 Capital Management LP

Ask AI
Doc SearchProfileEntity Structure

Overview

ProfileEntity Structure

Documents

SEC Filings
M

M28 Capital Management LP

Ask AI
Doc SearchProfileEntity Structure

Overview

ProfileEntity Structure

Documents

SEC Filings

M28 Capital Management LP — Company Profile

M28 Capital Management LP is a limited partnership headquartered in STAMFORD, US. As of August 2025, the firm reported $120.8 million in regulatory assets under management. The firm employs 1 investment adviser staff. Advisory services include portfolio mgmt pooled.

Sector
Financials
Industry
Capital Markets
Headquarters
STAMFORD, CT, US
Employees
3
Website
www.m28capital.com

Key Metrics

Price
$0.00
Market Cap
$0.00
Revenue (TTM)
$0.00
Net Income (TTM)
$0.00
EPS (TTM)
0.00
P/E (TTM)
0.00
P/B (TTM)
0.00
Dividend Yield
0.00%
ROE (TTM)
0.00%
ROA (TTM)
0.00%
Operating Margin
0.00%
Beta
0.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(46)

Expand
  • 13F-HRQuarterly report (institutional investment manager holdings)04:59PM
  • N-PXAnnual report of proxy voting record28 Aug
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Aug
  • Form 4M28 Capital Management LP21 May
  • 13F-HRQuarterly report (institutional investment manager holdings)14 May
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Feb
  • SC 13G/ACURIS INC23 Jan
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Nov 2025
  • N-PXAnnual report of proxy voting record28 Aug 2025
  • SC 13D/AInvivyd, Inc.26 Aug 2025
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Aug 2025
  • SC 13G/ACURIS INC13 Aug 2025
  • Form 4M28 Capital Management LP22 May 2025
  • 13F-HRQuarterly report (institutional investment manager holdings)14 May 2025
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Feb 2025
  • 13F-HRQuarterly report (institutional investment manager holdings)12 Nov 2024
  • SC 13G/AWave Life Sciences Ltd.12 Nov 2024
  • N-PXAnnual report of proxy voting record30 Aug 2024
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Aug 2024
  • Form 4M28 Capital Management LP23 May 2024

Mentions in Filings

  • M
    … member of the Board since June 2022 and as Chairman of the Board since July 2022. He previously served as a member of the Board from July 2020 to April 2021. Mr. Elia is the founder and chief investment officer of <strong>M28 Capital Management</strong> L.P., a healthcare sector investment fund, positions he has held since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. E …
    Invivyd, Inc.M28 Capital Management LP·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q3 26·1 Sep
  • M
    … Adagio Therapeutics, Inc.), a publicly-held biotechnology company developing antibodies against viruses, since June 2021, and has served as the chairman of the board since 2022. In September 2019, Mr. Elia founded <strong>M28 Capital Management</strong>, a healthcare sector investment fund, and serves as its Chief Investment Officer. Mr. Elia has also served as a director and audit committee member at SQZ Biotech, a publicly traded clinical-stage biotechnology co …
    FRACTYL HEALTH, INC.M28 Capital Management LP·DEF 14A - Definitive proxy statement·Q2 26·24 Apr
  • M
    Marc Elia has served as a member of our Board since June 2022 and as Chairperson of our Board since July 2022. Mr. Elia is the founder and chief investment officer of <strong>M28 Capital Management</strong> L.P., a healthcare sector investment fund, positions he has held since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. Elia currently serves on the board of directors …
    Invivyd, Inc.M28 Capital Management LP·DEF 14A - Definitive proxy statement·Q2 26·6 Apr

M28 Capital Management LP — Company Profile

M28 Capital Management LP is a limited partnership headquartered in STAMFORD, US. As of August 2025, the firm reported $120.8 million in regulatory assets under management. The firm employs 1 investment adviser staff. Advisory services include portfolio mgmt pooled.

Sector
Financials
Industry
Capital Markets
Headquarters
STAMFORD, CT, US
Employees
3
Website
www.m28capital.com

Key Metrics

Price
$0.00
Market Cap
$0.00
Revenue (TTM)
$0.00
Net Income (TTM)
$0.00
EPS (TTM)
0.00
P/E (TTM)
0.00
P/B (TTM)
0.00
Dividend Yield
0.00%
ROE (TTM)
0.00%
ROA (TTM)
0.00%
Operating Margin
0.00%
Beta
0.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(46)

Expand
  • 13F-HRQuarterly report (institutional investment manager holdings)04:59PM
  • N-PXAnnual report of proxy voting record28 Aug
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Aug
  • Form 4M28 Capital Management LP21 May
  • 13F-HRQuarterly report (institutional investment manager holdings)14 May
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Feb
  • SC 13G/ACURIS INC23 Jan
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Nov 2025
  • N-PXAnnual report of proxy voting record28 Aug 2025
  • SC 13D/AInvivyd, Inc.26 Aug 2025
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Aug 2025
  • SC 13G/ACURIS INC13 Aug 2025
  • Form 4M28 Capital Management LP22 May 2025
  • 13F-HRQuarterly report (institutional investment manager holdings)14 May 2025
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Feb 2025
  • 13F-HRQuarterly report (institutional investment manager holdings)12 Nov 2024
  • SC 13G/AWave Life Sciences Ltd.12 Nov 2024
  • N-PXAnnual report of proxy voting record30 Aug 2024
  • 13F-HRQuarterly report (institutional investment manager holdings)13 Aug 2024
  • Form 4M28 Capital Management LP23 May 2024

Mentions in Filings

  • M
    … member of the Board since June 2022 and as Chairman of the Board since July 2022. He previously served as a member of the Board from July 2020 to April 2021. Mr. Elia is the founder and chief investment officer of <strong>M28 Capital Management</strong> L.P., a healthcare sector investment fund, positions he has held since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. E …
    Invivyd, Inc.M28 Capital Management LP·8-K - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers·Q3 26·1 Sep
  • M
    … Adagio Therapeutics, Inc.), a publicly-held biotechnology company developing antibodies against viruses, since June 2021, and has served as the chairman of the board since 2022. In September 2019, Mr. Elia founded <strong>M28 Capital Management</strong>, a healthcare sector investment fund, and serves as its Chief Investment Officer. Mr. Elia has also served as a director and audit committee member at SQZ Biotech, a publicly traded clinical-stage biotechnology co …
    FRACTYL HEALTH, INC.M28 Capital Management LP·DEF 14A - Definitive proxy statement·Q2 26·24 Apr
  • M
    Marc Elia has served as a member of our Board since June 2022 and as Chairperson of our Board since July 2022. Mr. Elia is the founder and chief investment officer of <strong>M28 Capital Management</strong> L.P., a healthcare sector investment fund, positions he has held since September 2019. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. Mr. Elia currently serves on the board of directors …
    Invivyd, Inc.M28 Capital Management LP·DEF 14A - Definitive proxy statement·Q2 26·6 Apr